BMS's Onglyza gets first nod for diabetes in EU
This article was originally published in Scrip
Executive Summary
The CHMP has adopted a positive opinion on Bristol-Myers Squibb/AstraZeneca's Onglyza (saxagliptin) for type 2 diabetes as an add-on combination therapy to metformin, a thiazolidinedione, or a sulphonylurea.